At the time of writing, Perspective Therapeutics Inc [CATX] stock is trading at $2.21, up 6.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CATX shares have lost -0.45% over the last week, with a monthly amount drifted -50.78%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on October 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $14. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 13, 2025, and set its price target to $10. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $15 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $5 on November 25, 2024. UBS initiated its recommendation with a Buy and recommended $20 as its price target on October 24, 2024. Wedbush started tracking with an Outperform rating for this stock on October 01, 2024, and assigned it a price target of $25. In a note dated September 25, 2024, Truist initiated a Buy rating and provided a target price of $21 on this stock.
For the past year, the stock price of Perspective Therapeutics Inc fluctuated between $1.60 and $8.93. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $2.21 at the most recent close of the market. An investor can expect a potential return of 533.48% based on the average CATX price forecast.
Analyzing the CATX fundamentals
According to Perspective Therapeutics Inc [AMEX:CATX], the company’s sales were 1.07M for trailing twelve months, which represents an -43.36% plunge. Gross Profit Margin for this corporation currently stands at -1.5% with Operating Profit Margin at -184.63%, Pretax Profit Margin comes in at -204.47%, and Net Profit Margin reading is -197.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.39 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.08 points at the first support level, and at 1.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.33, and for the 2nd resistance point, it is at 2.45.
Ratios To Look Out For
It is important to note that Perspective Therapeutics Inc [AMEX:CATX] has a current ratio of 8.66. Also, the Quick Ratio is 8.66, while the Cash Ratio stands at 2.22. Considering the valuation of this stock, the price to sales ratio is 153.54, the price to book ratio is 0.68.
Transactions by insiders
Recent insider trading involved Hunt Jonathan Robert, Chief Accounting Officer, that happened on Nov 13 ’25 when 11000.0 shares were purchased. Director, Williamson Robert F III completed a deal on Nov 12 ’25 to buy 9498.0 shares. Meanwhile, Chief Executive Officer Spoor Johan M. bought 22026.0 shares on Mar 28 ’25.
